Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label multicenter phase IV study of decitabine dose and regimen strategies in myelodysplastic syndrome
CTR20180506Phase 4Suspended
- Sponsor
- JARI Pharmaceutical
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of decitabine in myelodysplastic syndrome (MDS), sponsored by JARI Pharmaceutical. Started Aug 2018; status: suspended.
02
Drugs
decitabine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on CTR20180506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180506.